USPTO serial 90886631
ELLIPSES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 7, 2025
- Examiner
- MOSCATI, JUSTIN RONALD
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ELLIPSES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John C. Cain
John C. Cain Munck Wilson Mandala, LLP1330 Post Oak Boulevard, Suite 2850Houston, TX 77056United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of cancer; veterinary preparations for the treatment of cancer; dietetic preparations for medical purposes; dietetic foods for use in clinical nutrition; food supplements; nutraceuticals for therapeutic and medical purposes; medicated food supplements; biological preparations for the treatment of cancer; anti-cancer preparations; anti-cancer drugs being preparations; compounds for treating cancer being pharmaceutical preparations; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; all of the aforesaid for use in oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer | ACTIVE | — |
| 042 | Medical and pharmacological research services; biological research; clinical research in the field of oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and surgery in relation to cancer; medical research; providing an online network environment for research and development for drug and pharmaceutical development; providing an online network environment for the design, development and testing of drugs and pharmaceuticals; Providing scientific and technological services and research, analysis, and design relating thereto; design, development and testing of drugs and pharmaceuticals for the treatment and/or prevention of cancer; laboratory research into new drugs and pharmaceutical products; pharmaceutical drug development services; research relating into medicines; consultancy services relating to scientific and medical research; expert advice relating to drug development, being consulting services in the field of pharmaceutical research; laboratory analysis in the field of pharmaceutical research; computer hardware and software design and development in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; computer network services in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; software hosting services in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; software as a service in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; Information Technology (IT) consultancy, advisory and information services relating to a network of medical research professionals; scientific advisory services; scientific research projects and studies being scientific research and development; conducting clinical trials being scientific and medical research for others; scientific and medical clinical research for others; clinical research for cancer treatments and pharmaceuticals; providing an online network environment for clinical trials; conducting and collating a research network for treatment, cure and prevention of cancer being medical and scientific research; development of measuring and testing methods being research and development in the field of pharmaceuticals; quality control of services; evaluation of drug development services; industrial testing, namely, industrial design services; pharmaceutical product evaluation; testing of chemicals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Ellipses Pharma Ltd
- Other trademarks owned by Ellipses Pharma Ltd
- Other trademarks owned by Ellipses Pharma Ltd
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ELLIPSES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 7, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 7, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 3, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 19, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 19, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 13, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 10, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 14, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| May 14, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 14, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 14, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 6, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 21, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 21, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 21, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 21, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 8, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 7, 2024 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Dec 29, 2023 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jun 8, 2023 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 25, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Nov 25, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Nov 25, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Nov 24, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 23, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 23, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 23, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 23, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 23, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 18, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 5, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 20, 2021 | NWAP | NEW APPLICATION ENTERED | — |